W

bioLLM/wiki

LLM-Synthesized Biotech Database

Live

RANKL/RANK signaling pathway

RANKL/RANK signaling pathway

Overview

The RANKL/RANK signaling pathway is a central cell communication axis in bone biology and immune regulation. It is initiated by RANKL (receptor activator of nuclear factor-κB ligand) binding to its receptor RANK on target cells, especially osteoclast precursors. This interaction promotes osteoclast differentiation, activation, and survival, thereby driving bone resorption. Because of this role, the pathway is a major regulator of skeletal remodeling and a key therapeutic target in diseases characterized by excessive osteoclast activity.

Beyond normal bone turnover, RANKL/RANK signaling is implicated in pathological bone loss, osteoarthritis-associated bone changes, and tumor–bone microenvironment interactions. In recent biomedical research, the pathway has been studied in contexts including osteoclastogenesis, osteoblast-osteoclast balance, Age-related osteogenic failure, and bone metastasis. Therapeutic inhibition of RANKL, such as with denosumab, is clinically relevant in settings such as giant cell tumor of bone and metastatic bone disease, while newer studies continue to explore RANKL-dependent and RANKL-independent mechanisms in osteoclast biology.

Recent Publications Focus

Below is a summary of the newest research publications targeting RANKL/RANK signaling pathway (sorted by publication date).

  • PMID: 42033613 — Osteoclast Precursor Membrane-Coated Nanoparticles Loaded With Abaloparatide Enable Dual Modulation of Osteoclast and Osteoblast Differentiation.
    This study examined nanodrugs designed with osteoclast precursor membrane-coated nanoparticles loaded with abaloparatide to achieve dual effects on bone remodeling. In osteoclast precursors, the formulation suppressed RANKL-induced differentiation without affecting cell viability, and it downregulated osteoclast-associated markers including CTSK, NFATc1, and TRAP. The work used methods and readouts such as western blot, flow cytometric techniques, and osteogenic measurements including RUNX2 and ALP, along with Alizarin Red S staining. Overall, the publication supports the idea that targeting the RANKL/RANK axis can be integrated into biomimetic delivery systems to inhibit osteoclastogenesis while promoting osteogenic responses.

  • PMID: 42379792 — Giant Cell Tumor of the Cervical Axis Treated With Anterior-Posterior Surgery and Denosumab: A Ten-year Follow-up Case Report.
    This case report describes the use of denosumab, a monoclonal antibody targeting RANKL, as an adjuvant therapy in a surgically challenging giant cell tumor of bone involving the cervical axis. The report emphasizes denosumab’s role in unresectable or difficult-to-resect disease, where suppression of RANKL-mediated osteoclast activity can complement surgery. The publication highlights long-term follow-up after anterior-posterior surgery and denosumab treatment, reinforcing the clinical relevance of RANKL inhibition in bone tumors.

  • PMID: 42203310 — A RANKL-derived Peptide Inhibits RSPO3-LGR4-Wnt Signaling and Lung Adenocarcinoma in Mice.
    This study investigated a RANKL-derived peptide in the context of lung adenocarcinoma and found that it inhibited RSPO3-LGR4-Wnt signaling in mice. The publication notes that LGR4 is also a receptor for RANKL, linking the pathway to signaling networks beyond bone. The work used A549 lung cancer cells, Transwell co-culture system, and related experimental approaches to explore tumor biology. By connecting RANKL-related signaling to Wnt pathway modulation, the study suggests broader roles for RANKL/RANK-associated biology in cancer progression and tumor–microenvironment interactions, including contexts relevant to lung cancer brain metastases.

  • PMID: 42138086 — Targeting RANKL-independent osteoclastogenesis overcomes denosumab resistance in models of ER+ breast cancer bone metastasis.
    This publication addresses a major therapeutic challenge in estrogen receptor-positive breast cancer with bone metastasis: the emergence of denosumab resistance. The study focused on RANKL-independent osteoclastogenesis, indicating that osteoclast activation can persist even when RANKL is inhibited. The findings suggest that alternative osteoclastogenic mechanisms may sustain bone destruction and metastatic progression despite RANKL blockade. This work is directly relevant to the clinical use of RANKL-targeted therapy in metastatic bone disease and underscores the need for combination or alternative strategies when resistance develops.

  • PMID: 41921366 — Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2- breast cancer patients with bone metastases receiving Cdk4/6 inhibitors: A multicenter Italian study.
    This multicenter real-world study evaluated denosumab in BRCA1/2-mutated HR+/HER2- breast cancer patients with bone metastases receiving Cdk4/6 inhibitors. The authors report that RANKL inhibition with denosumab could disrupt tumor-bone microenvironment crosstalk and potentially limit metastatic progression. The study links RANKL-targeted therapy to improved progression-free survival in this clinical setting, supporting the relevance of the pathway in metastatic breast cancer management and in the interaction between tumor cells, bone, and immune/stromal components such as macrophage populations.

  • PMID: 42067949 — SIRT1 Downregulation by Advanced Glycation End Products Activates RANKL-Dependent Osteoclast Signaling and Drives Chondrocyte senescence During Osteoarthritis Development.
    This study explored how advanced glycation end products influence osteoarticular pathology by downregulating SIRT1, thereby activating RANKL-dependent osteoclast signaling and promoting chondrocyte senescence during osteoarthritis development. The work used an OA mouse model, small hairpin RNA, western blot, and receptor for advanced glycation end products-related analyses to dissect the mechanism. The findings indicate that loss of SIRT1 deacetylase activity enhances RANKL/RANK signaling and osteoclast differentiation, linking metabolic stress to degenerative joint disease and reinforcing the pathway’s role beyond classic osteoporosis.

Target PMIDs

  • [PMID 42033613]
  • [PMID 42379792]
  • [PMID 42203310]
  • [PMID 42138086]
  • [PMID 41921366]
  • [PMID 42067949]
Content is generated using Large Language Models (LLMs) and may contain errors or hallucinations. Experts periodically review it to verify accuracy and maintain database integrity.